Illumina Q3 2026 revenue rises 4.2%, boosts full-year outlook on strong clinical demand and AI innovation.

Illumina reported Q3 2026 revenue of $1.13 billion, up 4.2% from the previous year, driven by strong clinical demand and NovaSeq X placements. The company raised its full-year revenue guidance to $4.64-$4.66 billion and non-GAAP EPS to $5.40-$5.45, reflecting continued momentum. Illumina highlights its expanding innovation ecosystem, including AI applications to improve human biology understanding and patient outcomes. Cash flow and operating margins also improved, supporting the positive outlook.

Despite Illumina's strong Q3 revenue growth and raised full-year guidance, its stock price on Pluang has dropped sharply by 14.82% to USD 246.00 as of Oct 30, 2026 03:12 WIB. This price is closer to the 52-week high of USD 293.69 than the low of USD 95.03, yet current Pluang order activity shows 100% selling, indicating a strong sell sentiment among investors at this level.